Last reviewed · How we verify

Asacol (mesalamine) — Competitive Intelligence Brief

Asacol (mesalamine) (Asacol (mesalamine)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-aminosalicylic acid (5-ASA) agent. Area: Gastroenterology / Immunology.

marketed 5-aminosalicylic acid (5-ASA) agent Prostaglandin and leukotriene synthesis inhibition; free radical scavenging Gastroenterology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Asacol (mesalamine) (Asacol (mesalamine)) — University of Washington. Mesalamine is an anti-inflammatory agent that acts locally in the colon to reduce inflammation by inhibiting prostaglandin and leukotriene production.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Asacol (mesalamine) TARGET Asacol (mesalamine) University of Washington marketed 5-aminosalicylic acid (5-ASA) agent Prostaglandin and leukotriene synthesis inhibition; free radical scavenging
MMX Mesalamine MMX Mesalamine Shire marketed 5-aminosalicylic acid (5-ASA) agent Prostaglandin and leukotriene pathways (topical anti-inflammatory)
MMX mesalamine/ mesalazine MMX mesalamine/ mesalazine Shire marketed 5-aminosalicylic acid (5-ASA) agent Prostaglandin and leukotriene synthesis; non-selective anti-inflammatory mechanism
sulphasalazine (SSZ) sulphasalazine (SSZ) Wyeth is now a wholly owned subsidiary of Pfizer marketed 5-aminosalicylic acid (5-ASA) agent Prostaglandin and leukotriene synthesis inhibition; NF-κB pathway modulation
Mesalazine(asacol 800 mg) Mesalazine(asacol 800 mg) Tehran University of Medical Sciences marketed 5-aminosalicylic acid (5-ASA) agent Prostaglandin and leukotriene synthesis; nuclear factor-kappa B (NF-κB) pathway
Granulated mesalamine Granulated mesalamine Bausch Health Americas, Inc. phase 3 5-aminosalicylic acid (5-ASA) agent Prostaglandin and leukotriene synthesis inhibition

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-aminosalicylic acid (5-ASA) agent class)

  1. Shire · 2 drugs in this class
  2. Bausch Health Americas, Inc. · 1 drug in this class
  3. Tehran University of Medical Sciences · 1 drug in this class
  4. University of Washington · 1 drug in this class
  5. Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Asacol (mesalamine) — Competitive Intelligence Brief. https://druglandscape.com/ci/asacol-mesalamine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing